You might also like
NeuroOne Medical Technologies Corporation (NMTC) is a medical technology company specializing in the development and commercialization of thin film electrode technology for neurological and related disorders. The company focuses on providing innovative solutions for diagnosing and treating conditions such as epilepsy, Parkinson's disease, chronic pain, and other brain or motor-related disorders. NMTC's product portfolio includes FDA-cleared devices for brain activity monitoring, stimulation, and ablation, as well as ongoing research into advanced therapeutic applications.
- OneRF™ Ablation System - Creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures, with FDA clearance and a commercial launch initiated in 2024.
- Evo® sEEG Electrode - Used for stereoelectroencephalography (sEEG), a diagnostic procedure for epilepsy, enabling recording, monitoring, and stimulation of subsurface brain activity.
- Evo Cortical Electrode Technology - Records, monitors, and stimulates brain tissue for up to 30 days, supporting diagnostic and therapeutic applications.
- Strip/Grid Products and Electrode Cable Assembly Products - Includes electrodes and cables for continuous electroencephalogram (cEEG) monitoring and other neurological applications.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David Rosa ExecutiveBoard | Chief Executive Officer, President, and Director | Director at Biotricity Inc. (Nasdaq: BTCY), BioRestorative Therapies, Inc. (Nasdaq: BRTX), and Healthcare Triangle, Inc. (Nasdaq: HCTI) | David Rosa has been CEO, President, and Director of NMTC since July 2017. He has extensive experience in the medical device industry and has provided critical strategic and operational leadership to NMTC. | View Report → |
Christopher Volker Executive | Chief Operating Officer | None | Christopher Volker became COO of NMTC in November 2023. He previously held leadership roles at Abbott Laboratories and Cardiovascular Systems, Inc., where he managed international business operations and strategic planning. | |
Mark Christianson Executive | Business Development Director and Medical Sales Liaison | None | Mark Christianson has been with NMTC since December 2016, initially as VP of Sales and Marketing. He has over 15 years of experience in sales, sales management, and project management in the neurological field. | |
Ronald McClurg Executive | Chief Financial Officer | Board of Governors at Biomagnetic Sciences, LLC; Director and Audit Committee Chair at Biotricity, Inc. (Nasdaq: BTCY) and Healthcare Triangle, Inc. (Nasdaq: HCTI) | Ronald McClurg has been CFO of NMTC since January 2021. He has a strong background in financial leadership, having served as CFO for multiple companies, including Incisive Surgical and Wavecrest Corporation. | |
Steve Mertens Executive | Chief Technology Officer | Board member at University Enterprise Laboratories | Steve Mertens has been CTO of NMTC since April 2019. He has extensive experience in product development and operations, having held senior roles at Nuvaira Inc. and Boston Scientific Corporation. | |
Edward Andrle Board | Director | Chairman of the Board and Co-Founder of Arcos Interventional, Inc.; Board Member at Rainbow Medical | Edward Andrle has been a Director at NMTC since February 2020. He has significant experience in medical device companies and business development, having co-founded multiple companies and held leadership roles at LivaNova PLC and Boston Scientific, Inc. | |
Jeffrey Mathiesen Board | Director | CFO, Treasurer, and Secretary at Helius Medical Technologies, Inc. (Nasdaq: HSDT); Vice Chair and Lead Independent Director at Panbela Therapeutics, Inc. (Nasdaq: PBLA) | Jeffrey Mathiesen has been a Director at NMTC since August 2017. He has extensive financial expertise and experience in public company accounting, having served as CFO for multiple companies, including Sunshine Heart, Inc. and Gemphire Therapeutics Inc. | |
Paul Buckman Board | Chairman of the Board | CEO of Rhythmlink International LLC; Director at Helius Medical Technologies, Inc. (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., and Shoulder Innovations, Inc.; Chairman at Miromatrix, Inc. | Paul Buckman has been Chairman of the Board at NMTC since August 2017. He has over 30 years of experience in the medical device industry, having held leadership roles at companies like LivaNova PLC and ev3, LLC, which he founded and grew into a significant business. |
- With net losses increasing to $12.3 million in fiscal year 2024 and cash decreasing to $1.5 million, how does the company plan to fund operations and achieve its aggressive revenue growth targets without further diluting shareholders?
- Your fiscal year 2025 revenue guidance of $8 million to $10 million represents significant growth over fiscal 2024; what are the key assumptions driving this projection, and what risks could prevent you from achieving these targets?
- R&D expenses decreased by 27% in fiscal year 2024; how do you plan to sustain and accelerate product development for new indications like trigeminal neuralgia and spinal cord stimulation with reduced R&D spending?
- Given the company's non-compliance with NASDAQ's minimum bid price requirement, what specific strategies are you considering to regain compliance, and how might these actions affect existing shareholders?
- Since potential revenue from the trigeminal nerve indication is not included in your fiscal year 2025 guidance, how would delays or setbacks in FDA approval for this indication impact your future growth expectations?
Recent developments and announcements about NMTC.
Earnings
New Earnings (Q1 2025)
·Feb 12, 2025, 4:27 PMView full earnings summary →NMTC’s OneRF ablation yields 9+ months seizure-free, showing strong potential. Q1 margin hit 60%, normalizing to 47–51%. A 1H25 510(k) for 150K trigeminal neuralgia patients could drive growth beyond current guidance, underscoring a major opportunity.